E.S. LEONOVA^1,2, S.V. POLYAKOV^1,2, М.А. POZDNYAKOVA², Е.P. YARYGINA³, S.O. SEMISYNOV²

¹Railway Clinical Hospital at the station Gor’kiy of JSC Russian Railways, Inter Railway Center of Ophthalmology, 18 Lenina Ave., Nizhny Novgorod, Russian Federation, 603140

²Nizhny Novgorod State Medical Academy, 10/1 Minina i Pozharskogo Sq., Nizhny Novgorod, Russian Federation, 603950

³City Hospital No. 35, City Center of Glaucoma, 15 Osharskaya St., Nizhny Novgorod, Russian Federation, 603005

Leonova E.S. — Dr. Med. Sc., Associate Professor

Polyakov S.V. — ophthalmologist, post-graduate student of the Department, e-mail: psv152@yandex.ru

Pozdnyakova M.A. — Dr. Med. Sc., Professor

Yarygina E.P. — ophthalmologist of the highest category, Head of the City center of glaucoma

Semisynov S.O. — Candidate of Medical Sciences, Associate Professor

The aim was to develop an algorithm of the neuroprotective therapy in course of the follow-up monitoring of railway workers with primary open-angle glaucoma (POAG) on the basis of an assessment of the effectiveness of a phased application of intravenous and tablet form of the drug «Mexidol». Materials and methods: All kinds of JSC Russian Railways employees with POAG of stages I-III and compensated level of intraocular pressure were included in the study. Mexidol was subject to intravenous drip-feed — 250 mg intravenously for 5 days in the mode of the day hospital, after that outpatient — 125 mg three times per day orally for 3 months. Upon the first, the second and the third visits, the patients underwent a comprehensive ophthalmology examination with the use of high-tech control techniques. Results: Data from 58 patients (96 eyes) were analyzed. Significant improvement in perimetry, optical coherence tomography was obtained only on the third visit, upon completion of the treatment course with Mexidol. In patients with I-II stage of the disease was observed the greatest effect of the conducted neuroprotective therapy. Conclusion: The results suggest patients with primary open-angle glaucoma the combination therapy with Mexidol intravenous and tablets, as well as long-term (three months) administration of Mexidol tablets. It has been also found that neuroprotective therapy with Mexidol is mostly effective in the early phase of the disease.

Key words: glaucoma, neuroprotective therapy, Mexidol, follow-up monitoring.